Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Japan Q1 Roundup: Enhertu, Padcev, Actemra and Lenvima Push Growth

09 Aug 2022

• By Lisa Takagi

Japan q1 round up — Daiichi Sankyo, Chugai, Astellas, Eisai show stable Q1 growth • Source: Shutterstock

Related Content

Gene Therapy Situation Gets More Awkward With Another Death In Astellas XLMTM Study

15 Sep 2021

Enhertu Goes Into High Gear With HER2-Low Breast Cancer Approval

05 Aug 2022

Padcev/Keytruda Results Could Sweeten Potential Seagen/Merck Deal

26 Jul 2022

Daiichi Eyes First-Line AML Filings For Vanflyta On Positive Data

17 Jun 2022

ASCO: AstraZeneca's Enhertu Is Poised To Change The Breast Cancer Paradigm

06 Jun 2022

Related Companies

Daiichi Sankyo Co., Ltd.

Astellas Pharma, Inc.

Chugai Pharmaceutical Co., Ltd.

Eisai Co., Ltd.

Roche Holding AG

Astellas Gene Therapies

Maruho Co., Ltd.

Bristol Myers Squibb Company

Biogen, Inc.

Additional Topics

Japan Asia Pacific Business Strategies Research & Development BioPharmaceutical

More from Japan

More from Focus On Asia

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.